Pulmatrix (NASDAQ:PULM) activated three U.S. sites for its Phase 2 clinical trial of pulmazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The primary objective of the...
Tilray (NASDAQ:TLRY) welcomed five individuals to its leadership team to support the company’s aggressive European and international expansion strategy. Tilray appointed Arne Wilkens as VP business expansion; José...
Bellicum Pharmaceuticals’ (NASDAQ:BLCM) registrational trial of rivo-cel achieved its primary endpoint of event-free survival when the drug was administered to patients receiving stem cell transplants.
Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR001, a gene therapy candidate for the treatment of Parkinson’s disease (PD).
The FDA approved Karyopharm Therapeutics (NASDAQ:KPTI) XPOVIO, in combination with dexamethasone, for the treatment of relapsed or refractory multiple myeloma (RRMM).
Ovid Therapeutics (NASDAQ: PTI) reported that, following a positive opinion from the European Medicines Agency, the European Commission granted OV101 orphan drug designation for the treatment of Angelman syndrome.
Zenabis Global (TSX:ZENA) entered into an agreement with High Park Holdings, a wholly-owned unit of Tilray (NASDAQ:TLRY), for High Park to advance $30- million (Canadian) to Zenabis in return for a supply of dried...
Arcturus Therapeutics (NASDAQ:ARCT) received FDA orphan drug designation for ARCT-810 for the treatment of ornithine transcarbamylase (OTC) deficiency.
Following a Type A meeting with the FDA, Zogenix (NASDAQ:ZGNX) reported that it plans to resubmit its NDA for FINTEPLA for the treatment of seizures associated with Dravet syndrome.
Dova Pharmaceuticals (NASDAQ:DOVA) reported that the FDA approved DOPTELET’s supplemental NDA, expanding its use to include the treatment of adults with chronic immune thrombocytopenia (ITP) who have not responded to...
Aridis Pharmaceuticals (NASDAQ:ARDS) received FDA orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF).
Novavax (NASDAQ:NVAX) reported that the FDA recently made the accelerated approval pathway available for NanoFlu, and that Novavax will be pursuing that pathway for licensure of the vaccine.
Zenabis Global (TSX:ZENA) will use TruTrace Technologies’ (CSE:TTT; OTC:BKKSF) StrainSecure platform to collect, register, manage, track and publish verified testing data of its cannabis plant DNA and strains, and...
Dare Bioscience (NASDAQ:DARE) completed patient recruitment for a postcoital test (PCT) trial of Ovaprene, a self-administered, hormone-free, contraceptive intravaginal ring.
Inovio Pharmaceuticals (NASDAQ:INO) reached target enrollment of 198 women for its pivotal Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia caused by human papillomavirus (HPV).
Precipio (NASDAQ:PRPO) and closely-held H3 Biomedicine began a second development project to create a targeted gene panel that H3 will use in its ongoing clinical programs.
Dova Pharmaceuticals’ (NASDAQ:DOVA) DOPTELET has been granted European Commission (EC) marketing authorization for the treatment of severe thrombocytopenia in patients with chronic liver disease (CLD).